HYPERPHOSPHATEMIA

This study tested the long-term safety of a drug called MCI-196 in 116 adults with advanced chronic kidney disease who are on dialysis and have high phosphorus levels. The goal was to see if the drug is safe and helps control phosphorus over a year. Participants took flexible dos…

This study tested a drug called MCI-196 in 245 adults on dialysis with high phosphate levels. After a 12-week dose adjustment period, some patients switched to a placebo for 4 weeks to see if the drug truly kept phosphate levels down. The goal was to manage a common complication …

This study tested a new drug called AP301 in 474 adults with kidney failure who are on dialysis and have high phosphorus levels. High phosphorus can cause bone and heart problems. The goal was to see if AP301 lowers phosphorus better than the current standard treatment, sevelamer…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with advanced kidney disease on dialysis who have high phosphorus levels. Participants took the drug for up to 52 weeks to see how well it controls phosphorus and lowers LDL cholesterol. The goal is to …

This study tested a drug called MCI-196 in 642 adults on dialysis who had high phosphorus and cholesterol levels. Participants took either MCI-196 or a placebo for 12 weeks to see if the drug could safely lower both phosphorus and LDL cholesterol. The goal is to help manage heart…

This study tested a drug called MCI-196 to see if it can lower high phosphorus levels in people with advanced kidney disease who are on dialysis. High phosphorus can cause serious health problems. The trial involved 336 adults and compared MCI-196 to a placebo over several weeks.…

This study looked at how colestilan, a drug that lowers phosphate levels, changes the way the body absorbs candesartan, a blood pressure medicine. 18 healthy men took candesartan at different times around their colestilan dose. The goal was to see if timing matters, so doctors ca…